This trial is studying the combination of venetoclax and selinexor to see how well it works in treating patients with high-risk blood cancers that have come back or do not respond to initial treatment.
- Acute Myeloid Leukemia
- Non-Hodgkin's Lymphoma
- Diffuse Large B-Cell Lymphoma
2 Primary · 2 Secondary · Reporting Duration: Up to 2 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (venetoclax, selinexor)
1 of 1
78 Total Participants · 1 Treatment Group
Primary Treatment: Venetoclax · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any unfilled slots for volunteers in this experiment?
"Affirmative. According to clinicaltrials.gov, this experiment has been open for recruitment since June 21st 2019 and was most recently updated on August 12th 2022. 78 individuals must be enlisted from 4 distinct medical centres." - Anonymous Online Contributor
Have any other investigational trials been conducted with Venetoclax?
"Venetoclax, which was initially explored in 2014 at Children's Healthcare of Atlanta, has had 80 trials completed to date. Currently, there are 264 ongoing studies across the world - many taking place in Cleveland, Ohio." - Anonymous Online Contributor
How many participants are joining this research endeavor?
"Karyopharm Therapeutics Inc will manage the study from University Hospitals of Cleveland and Roswell Park Cancer Center. A total of 78 patients that satisfy the specified criteria must be enrolled to ensure its success." - Anonymous Online Contributor
How many centers are currently overseeing this clinical trial?
"This clinical trial is being conducted at University Hospitals of Cleveland in Cleveland, Ohio, Roswell Park Cancer Center in Buffalo, New York and the University of Texas Southwestern Medical Centre in Dallas. Additionally, there are 4 other sites where this research will take place." - Anonymous Online Contributor
Is this clinical experiment pioneering a new approach?
"Venetoclax has been under research since 2014, when Karyopharm Therapeutics Inc. conducted the inaugural clinical trial with a participant pool of 16 people. It then received Phase 1 drug approval and is now subject to 264 studies in 1284 cities across 48 nations." - Anonymous Online Contributor
What medical conditions is Venetoclax commonly employed to treat?
"Venetoclax has been used in therapeutic procedures and is known to be effective for small lymphocytic lymphoma, chronic lymphycytic leukemia (CLL), and intractable multiple myeloma." - Anonymous Online Contributor
Is Venetoclax a reliable approach to treatment with minimal risk?
"As it is a Phase 1 trial, which has limited evidence of efficacy and safety, our experts at Power rate the security of Venetoclax with a score of 1." - Anonymous Online Contributor